RxDoctor Payments Data

Lisa Smith, NP

Adult Health · Charleston, SCNPI 1952369043

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,464 of the $6,043 with a category attached, or 73.9%. 51 manufacturers reported payments, led by Novartis at 28.6% of the total. 2025 is the largest year on record at $2,558, 3.5 times the $731 reported in 2021.

$6,043in general payments, 2019–2025

Across 219 payments — averaging $27.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Bristol Myers Squibb$362
  • Merck$332
  • Astellas Pharma US Inc$256
  • Pfizer$214
  • Incyte Corporation$181
  • plus $3K from 45 others

What the payments were for

  • Food & beverage$4,46474%
  • Education$3997%
  • Other$1,18020%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,043 in reported general payments places this provider in the 85th percentile of 292 adult health providers in South Carolina.

See all adult health providers in South Carolina

Medicare billing

Part B allowed, 2024
$68,269
Medicare patients
263
Services billed
884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide23$412,728
BrukinsaZanubrutinib27$398,859
SprycelDasatinib22$376,141
TagrissoOsimertinib Mesylate17$276,604
KisqaliRibociclib Succinate11$184,686
PromactaEltrombopag Olamine12$85,798
EliquisApixaban58$33,019
VenclextaVenetoclax13$16,397
XareltoRivaroxaban11$13,988
Exemestane15$1,713
Anastrozole66$1,317
Letrozole45$1,307
Fluconazole14$547
Dexamethasone15$282
Acyclovir31$278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$362$412,72823 claims
Beigene USA, Inc.Brukinsa$57$398,85927 claims
E.r. Squibb & Sons, L.L.C.Sprycel$164$376,14122 claims
AstraZenecaTagrisso$142$276,60417 claims
NovartisKisqali, Promacta$1,727$270,48423 claims
PfizerEliquis$214$33,01958 claims
AbbVieVenclexta$110$16,39713 claims
Johnson & JohnsonXarelto$39$13,98811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 292 adult health providers in South Carolina.

Other adult health in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →